GMP Pharmaceuticals

Name

GMP Pharmaceuticals

Legal name

GMP Pharmaceuticals Pty Ltd

Website

https://gmp.com.au

Company type

Private

Founded year

1994

Operating status

Operating

Headcount range

251–500 employees

Ownership category

akta.pro rank

Product category

Contract Pharmaceutical Manufacturing

NAICS

Food Manufacturing (311), Pharmaceutical Preparation Manufacturing (325412), Packaging and Labeling Services (56191)

SIC

Food And Kindred Products (2000), Dairy Products (2020), Miscellaneous Food Preparations & Kindred Products (2090)

akta.pro primary industry

GMP Manufacturing Support Services (QA/QMS, validation, documentation) (HLAAAKAH)

akta.pro secondary industries

Specialty & Medical Infant Formula (Hypoallergenic, Lactose-Free, Metabolic) (CRADAEAB), Pharmaceutical Labels & Patient Information Packaging (Labels, IFUs, Booklets) (IMALAIAK), GMO/Non-GMO & Bioengineered Disclosure Verification (label compliance support) (AFALAHAH)

Keywords

• Contract manufacturing services
• Dietary supplement manufacturing
• Nutritional product formulation
• Pharmaceutical packaging services
• Regulatory compliance consulting

Headquarters

HQ city

Sydney

HQ country

Australia

HQ region

Oceania

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Infrastructure, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Contract Manufacturing Services: GMP operates as a contract manufacturer producing dietary supplements, functional foods, infant formulas, and nutritional products for brand owners and other businesses. Revenue is generated through manufacturing fees for producing client formulations across multiple dosage forms (tablets, capsules, powders, sachets, liquids, soft gels, freeze-dried products, gummies). Services span R&D, regulatory compliance, manufacturing, and packaging, providing an integrated one-stop solution.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

GMP Pharmaceuticals is a B2B contract manufacturer of dietary supplements, nutritional products, functional foods, and infant formulas for brand owner clients. Services span four integrated divisions: Research & Development (formulation, specification, stability testing), Regulatory Affairs (TGA, Medsafe, FDA, Chinese GB standards compliance), Manufacturing (across tablets, capsules, powders, liquids, sachets, soft gels, freeze-dried products, and gummies), and Packaging (bottles, jars, blisters, tins, sachets, custom formats). The company also markets the Cowala branded infant formula range with proprietary QR-code traceability.

Product overview

GMP Pharmaceuticals is a contract manufacturer offering integrated pharmaceutical and health supplement manufacturing services across four core divisions: R&D, Regulatory, Manufacturing, and Packaging. The company operates as a one-stop quality health food manufacturer providing end-to-end solutions from formulation through distribution. Their manufacturing portfolio includes tablets, capsules (hard shell and soft gel), powders, liquids, sachets, gummies, and freeze-dried products. Key product brands include Cowala infant formula with proprietary QR code traceability, and probiotic strains (Lacticaseibacillus rhamnosus HN001 and Bifidobacterium animalis subspecies lactis HN019) supplied exclusively from Fonterra. The company manufactures across five sites in Australia and New Zealand, serving international markets including China, with regulatory expertise spanning TGA, Medsafe, FDA, and Chinese GB standards.

Differentiator

Problem solved

Functional benefit

Brands

• Cowala: Cowala range of infant formula and adult milk powder products, marketed as 100% New Zealand products with patented traceability via 2D QR codes. Cowala was endorsed by the New Zealand Olympic Committee and became one of the top selling NZ infant formula brands in Korea's high-end supermarkets.
• NZMP SureStart

Products and services

• Contract Manufacturing Services

Quantifiable outcome

• 3 million cans of Cowala infant formula exported to China and Korea within approximately one year of partnership launch (November 2014 to December 2015)
• +1 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Six partnerships are on record, tiered core, flagship and minor.

• FonterracoreTechnology or Integration · 26 July 2020GMP signed an exclusive supply agreement with Fonterra (leading multinational dairy producer, approximately 30% of world dairy exports) for exclusive Australian supply of two clinically tested probiotic strains: Lacticaseibacillus rhamnosus HN001 (NZMP SureStart LactoB HN001) and Bifidobacterium animalis subspecies lactis HN019 (NZMP SureStart BifidoB HN019). These strains are used in formulas for children under 12 and pregnant/expecting mothers, supporting immune system health.
• New Zealand Olympic Committee (NZOC)flagshipGTM or Marketing Partner · 5 April 2016GMP became an official Partner with the NZOC and New Zealand Olympic Team for the Rio 2016 Summer Olympics and PyeongChang 2018 Winter Olympics. GMP signed as sole and exclusive partner in the powder-based nutritional formula category under the Cowala brand. The partnership was formalised through an official signing ceremony with NZOC CEO Kereyn Smith and GMP Dairy Managing Director Karl Ye. NZOC CEO stated the partnership is significant and GMP's support is a real boost to the team's preparation.
• University of SydneyminorOthersPartnership with the University of Sydney Faculty of Science for student placement programs. Supports GMP's talent pipeline and community engagement.
• AsureQualitycoreStrategic or Co-development PartnerAsureQuality (one of New Zealand's leading government-approved food safety auditing and testing organisations) partnered with Evergrande GMP Dairy to further enhance its food safety system. AsureQuality plays a vital role in ensuring foods produced in NZ are safe, providing end-to-end food supply chain focus through auditing, inspection, farm assurance, and laboratory testing.
• China Certification & Inspection Group (CCIC)coreStrategic or Co-development PartnerCCIC (an independent third-party certification and inspection organisation accredited by AQSIQ, CNCA, and CNAS) partnered with Evergrande GMP to provide inspection, verification, certification, and testing services, further enhancing the food safety and quality system.
• China Shipping NZminorStrategic or Co-development PartnerChina Shipping NZ partnered with Evergrande GMP Dairy as part of the Cowala Seamless Quality Protection Logistic System launch, providing shipping logistics services for the transportation of Cowala products from New Zealand to China.

Scale indicators6 records

Recent moves12 records

Expansion highlights4 records

Broad incumbents

• Lonza Group: Swiss-listed global CDMO leader with significant nutritional and oral-dose capabilities as well as capsules and health ingredients. Functions as a broad incumbent offering overlapping services but with much wider therapeutic and geographic scope than GMP.
• DSM-Firmenich: Global nutrition, health, and ingredient company with extensive supplement manufacturing and premix capabilities. Comparable in finished nutrition products and regulatory expertise, but operates at vastly larger scale across multiple health categories.
• Inner Mongolia Yili Industrial Group: China's largest dairy and infant formula company with fully integrated manufacturing including pediatric formula (Yili Gold). Competes with GMP/Cowala in the Chinese imported infant formula segment and represents a major counterparty/competitor for CDMO business tied to China.
• China Mengniu Dairy: One of China's two dominant dairy and infant formula companies (Mengniu, Yili). Direct competitor in the Chinese infant formula market where GMP/Cowala competes, and a potential strategic partner given comparable dominance across Chinese distribution.
• Catalent: Large global CDMO providing oral solid, softgel, and nutritional dose manufacturing including through its Gacona/Worldwide Capsoft acquisitions. Comparable end-to-end supplements CDMO offering, but at much larger scale and broader therapeutic diversification than GMP's nutraceutical focus.

Direct peers

• Sirio Pharma: China-headquartered nutraceutical and supplement CDMO with global footprint including Australia. Competes head-to-head for contract manufacturing of gummies, soft gels, tablets, and powders, particularly for Asian-market brand owners—the same customer segment GMP targets via its Beijing office.
• Blackmores Group: ASX-listed Australian dietary supplement and health products company operating across ANZ and Asia. Highly comparable in geographic footprint, regulatory environment (TGA), product categories, and target brand customers; operates both branded and contract manufacturing for health supplements.
• Mega Lifesciences: Asia-Pacific focused contract manufacturer and distributor of health and wellness products spanning nutraceuticals, pharmaceutical supplements, and personal care. Comparable CDMO model serving brand owners across Southeast Asia and Australasia with similar dosage-form breadth.
• Vitaco Holdings: NZ-based manufacturer of health, nutrition, and sports supplement brands (Musashi, Aussie Bodies) under Shanghai Pharmaceuticals ownership. Direct peer in ANZ contract manufacturing of dietary supplements and sports nutrition across multiple dosage forms with similar regulatory profile (TGA/Medsafe/FDA) and Asian export channels.

Emerging players

• Health and Happiness (H&H) Group / Biostime: HK-listed global infant nutrition and probiotics company (Biostime, Swisse, Aurelia London) with both branded infant formula and CDMO-style capabilities. Competes for the same premium Chinese maternal-and-infant consumer that the Cowala brand targets, and overlaps in probiotic-based formulations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/gmp-pharmaceuticals-ltd
• Xx.com/gmp_n

Compliance12 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GMP Pharmaceuticals